NSE ScannerComparison · NSE · data 2026-10-31
Beta Drugs Ltd. vs Syncom Formulation (India) Ltd.
In plain words
Size: Beta Drugs Ltd. is about 1.1 times the market value of Syncom Formulation (India) Ltd..
Valuation (P/E): Beta Drugs Ltd. 36.9 vs Syncom Formulation (India) Ltd. 21.2.
Profit growth over 3 years: Syncom Formulation (India) Ltd. 56.2% a year vs Beta Drugs Ltd. 10.5% a year.
Debt to equity: Beta Drugs Ltd. 0.62 vs Syncom Formulation (India) Ltd. 0.
Differences in the numbers, not a recommendation of either stock.
Side by side
| BETA | SYNCOMF | |
|---|---|---|
| Price | ₹1,798.4 | ₹19.24 |
| Market cap | ₹2,000 cr | ₹1,810 cr |
| P/E | 36.9 | 21.2 |
| P/B | 4.6 | — |
| ROE | 18.8% | 20.2% |
| ROCE | 16.6% | 16.3% |
| Debt / equity | 0.62 | 0 |
| Operating margin | 16.7% | 16.3% |
| Dividend yield | 0.00% | 0.52% |
| Sales growth, 3 years (yearly) | 19.2% | 29.4% |
| Profit growth, 3 years (yearly) | 10.5% | 56.2% |
| 1-year return | -4.8% | 16.0% |
| Revenue, last 12 months | ₹444 cr | ₹498 cr |
| Net profit, last 12 months | ₹52 cr | ₹86 cr |
| Latest quarter | Sept 2026 | — |
| Quarter net profit | ₹20 cr | — |
| Quarter profit vs a year earlier | — | — |
| Promoter holding | 58.91% | 50.57% |
| Health check | Strong (6.5/10) | Strong (8.4/10) |
Common questions
Which has a higher P/E, Beta Drugs Ltd. or Syncom Formulation (India) Ltd.?
Beta Drugs Ltd. trades at the higher P/E (36.9 against 21.2). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Syncom Formulation (India) Ltd. (20.2% against 18.8%).
Which carries more debt?
Beta Drugs Ltd. has the higher debt-to-equity ratio (0.62 against 0).